Search Results
Mar 23, 2026, 07:45 ET Craig Tendler, M.D., JNJ's Former Global Head of Oncology Clinical Development, to Lead TuHURA Bioscience's VISTA Program in AML and other Blood Related Cancers
treatments in prostate cancer (ZYTIGA®, AKEEGA®, and ERLEDA®), hematologic malignancies (DARZALEX®, CARVYKTI®, TECVAYLI®, TALVEY®, IMBRUVICA®) as well as for lung (RYBREVANT®) and bladder cancer (BALVERSA®). He has been a leader and key participant in four Oncology Drug Advisory Committee (ODAC) presentations,
More news about: TuHURA Biosciences, Inc.
Mar 23, 2026, 07:24 ET Interna Therapeutics Announces Human Challenge Trial Agreement with the University of Oxford to Advance Intranasal MNM-siRNA SARS-CoV-2 Prophylaxis Program
humans.Preclinical studies demonstrated potent antiviral efficacy, favourable safety, and efficient delivery of siRNA into respiratory tracts (nostrils and lung tissue), supporting progressing into clinical efficacy studies.About Interna TherapeuticsInterna Therapeutics is a clinical-stage
More news about: Interna Therapeutics
Mar 23, 2026, 07:00 ET Insmed Announces Positive Topline Results from Phase 3b ENCORE Study of ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in Patients with MAC Lung Disease
durable culture conversion at Month 15.About MAC Lung DiseaseMycobacterium avium complex (MAC) lung disease is a rare and serious disease that can significantly increase morbidity and mortality. Patients with MAC lung disease can experience a range of symptoms that often worsen
More news about: Insmed Incorporated
Mar 23, 2026, 05:02 ET Lung Cancer Survivors and Advocates Head to Capitol Hill to Champion Lifesaving Research, Prevention and Access to Care
LUNGFORCE.org.About the American Lung AssociationThe American Lung Association is the leading organization working to save lives by improving lung health and preventing lung disease through education, advocacy and research. The work of the American Lung Association is focused on four strategic
More news about: American Lung Association
Mar 23, 2026, 03:00 ET Coreline Soft Supplies Lung Cancer Screening AI to Charité - Universitätsmedizin Berlin
its lung cancer screening (LCS) AI solution to Charité – Universitätsmedizin Berlin, Germany's largest university hospital. This marks the company's entry into a core clinical hub for Germany's National Lung Cancer
More news about: Coreline Soft
Mar 21, 2026, 07:26 ET Dizal Announces Positive Topline Phase 3 Results from WU-KONG28 Study: Evaluating Oral, Once-Daily ZEGFROVY® (Sunvozertinib) vs. Platinum-Containing Chemo Doublet in First-Line Non-Small Cell Lung Cancer (NSCLC) with EGFR Exon 20 Insertion Mutation (exon20ins)
that its multinational Phase 3 WU-KONG28 study evaluating ZEGFROVY® (sunvozertinib) monotherapy as first-line treatment in non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations (exon20ins) met its primary endpoint with positive topline results.
More news about: Dizal
Mar 20, 2026, 09:03 ET Henlius Reports 2025 Results: Sustained Growth in Both Revenue and Profit, Advancing Innovation Validation and Global Operations
squamous non-small cell lung cancer (sqNSCLC). It has also been included in public reimbursement systems in seven EU countries, including Germany, Italy, and Spain. To date, serplulimab has been approved in over 40 countries and regions worldwide, with continued progress in lung and gastrointestinal cancers,
More news about: Henlius
Mar 20, 2026, 08:30 ET Caris Life Sciences Announces Another Breakthrough Study for GPSai in Identifying and Correcting Misdiagnosis of Cancer Patients
patients' treatments would achieve better outcomes. According to the CDC website, lung SCC accounts for roughly 21% of all lung cancer cases in the United States. Applying study-specific stats to the wider CDC data for lung cancer in the United States suggests that approximately 1,000 cases each year may
More news about: Caris Life Sciences
Mar 20, 2026, 08:00 ET FIRST ON THE WEST COAST: Eisenhower Lucy Curci Cancer Center Earns Lung Cancer Certification from The Joint Commission
Joint Commission's Gold Seal of Approval® for Lung Cancer Certification — the first on the West Coast — is an important recognition of Eisenhower Lucy Curci Cancer Center's commitment to delivering high-quality, evidence-based care for patients with lung cancer," says Katie Schnaser, Chief Administrative
More news about: Eisenhower Health
Mar 20, 2026, 05:06 ET Antengene Announces 2025 Full-Year Results: First TCE Out-licensing Validates Platform Value and Marks Inflection Point Towards 2026 Profitability
KEYTRUDA® (pembrolizumab) in patients with checkpoint inhibitor (CPI)-resistant melanoma and non-small cell lung cancer (NSCLC). These findings suggest that ATG-037 has clinically meaningful therapeutic potential in multiple tumor types, particularly in patients
More news about: Antengene Corporation Limited
Mar 20, 2026, 00:30 ET AeroDel signs exclusive licensing arrangement with Zydus for launching Aerolife Mini™, India's First Foldable, 'Always Attached' pMDI Enhancer
least one critical error while using inhaler devices, resulting in drug loss and reduced therapeutic benefit.Spacer devices are known to enhance lung deposition of pMDI-delivered drugs by reducing coordination errors. However, this segment remains largely undifferentiated — most existing products
More news about: Aerodel
Mar 19, 2026, 21:00 ET 德昇濟醫藥將於2026年AACR年會展示創新KRAS產品管線，一項摘要入選臨床試驗全體大會口頭報告
Safety and efficacy of Elisrasib (D3S-001), a next generation GDP-bound KRAS G12C inhibitor, as monotherapy in advanced non-small cell lung cancer (NSCLC) previously treated with or without a KRAS G12C inhibitor: Results from a phase 1/2 study 會議名稱：Clinical Trials Plenary 1:
More news about: 德昇濟醫藥（D3 Bio）
Mar 19, 2026, 21:00 ET D3 Bio to Showcase Its Innovative KRAS Pipeline at AACR 2026, Including an Oral Presentation at Clinical Plenary Session
Safety and efficacy of Elisrasib (D3S-001), a next generation GDP-bound KRAS G12C inhibitor, as monotherapy in advanced non-small cell lung cancer (NSCLC) previously treated with or without a KRAS G12C inhibitor: Results from a phase 1/2 studySession Title: Clinical
More news about: D3 Bio
Mar 19, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immutep Limited - IMMP
Monitoring Committee (IDMC) for the TACTI-004 Phase III study evaluating eftilagimod alfa ('efti') in patients in 1st line non-small cell lung cancer has recommended the discontinuation of the trial following a planned interim futility analysis in accordance with the study protocol." According
More news about: Pomerantz LLP
Mar 19, 2026, 09:44 ET CytoSorbents Announces HotSwap™ Launch, Renewed Aferetica Partnership, and New Clinical Evidence at ISICEM 2026
blood pumps already in the hospital (e.g. dialysis, continuous renal replacement therapy or CRRT, extracorporeal membrane oxygenation or ECMO, and heart-lung machines), where blood is repeatedly recirculated outside the body, through our cartridges where toxic substances are removed, and then back into the
More news about: Cytosorbents Corp
Mar 19, 2026, 08:17 ET CellCarta Secures Global Exclusivity for Biofidelity's Aspyre® Lung to Advance Targeted Lung Cancer Testing
year, the agreement allows sponsors to deploy Aspyre® Lung through a single, coordinated partner, simplifying lung cancer trial execution by reducing the need to manage multiple organizations for the same platform.Lung cancer clinical trials rely heavily on biomarker testing to guide
More news about: CellCarta
Mar 19, 2026, 08:00 ET Altesa BioSciences' Treatment for Rhinovirus Infections in People with Respiratory Conditions, Vapendavir, Selected for Oral Presentation at the International Society for Antiviral Research Conference (ICAR) 2026
established patient-reported outcomes, with additional endpoints evaluating time to symptom resolution, quality of life, healthcare resource utilization, and lung function."We are honored to present our novel data at ICAR, the premier international conference for antiviral research," said Dr. Brett Giroir,
More news about: Altesa Biosciences Inc.
Mar 19, 2026, 07:57 ET Brayton Purcell LLP Responds to CBS News Investigation on Rapidly Escalating Silicosis Crisis Among Artificial Stone Fabrication Workers
States are developing irreversible lung disease after cutting and polishing artificial stone, which releases clouds of nano‑sized particles that embed deeply into the lungs. Dr. Gounder noted that workers in their 30s and 40s are now presenting with end‑stage lung disease previously associated with decades‑long
More news about: Brayton Purcell LLP
Mar 19, 2026, 06:00 ET Top 5 Gundry MD Phyto Collagen Complex Reviews - Does It Really Work?
cardiothoracic surgeons before leaving his practice to pursue restorative medicine. Today, he is the founder and medical director of The International Heart and Lung Institute and The Centers for Restorative Medicine in Palm Springs and Montecito, California, where he has spent the past 30 years helping people restore
More news about: Gundry MD
Mar 18, 2026, 20:00 ET SystImmune, Inc. to Present New iza-bren (izalontamab brengitecan) Data in Extensive Stage Small Cell Lung Cancer at ELCC 2026
treatment-naive patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC) will be presented at ELCC. The data highlight the continued progress of iza-bren clinical development in China and build upon the previously reported clinical activity in lung, breast, and bladder cancer patients at ASCO, ESMO,
More news about: SystImmune, Inc.
Mar 18, 2026, 17:28 ET IMMP Investor Alert: Immutep Ltd. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Management Allegedly Misrepresented Trial Progress: Levi & Korsinsky
filing, Immutep described "strong operational progress" for the TACTI-004 (KEYNOTE-F91) Phase III trial of eftilagimod alfa in first-line non-small-cell lung cancer. The Company characterized the futility analysis as proceeding on schedule. Just six weeks later, the IDMC disclosed that the analysis had determined
More news about: Levi & Korsinsky
Mar 18, 2026, 17:18 ET Minnesota Radon Awareness Act Explained In HelloNation, Featuring Radon Expert Mitch Kelley
it is colorless and odorless, it cannot be detected without proper radon testing. Long-term exposure to elevated radon levels increases the risk of lung cancer, making awareness and evaluation a health consideration as well as a legal one.Although radon testing is not mandatory under the Minnesota
More news about: HelloNation
Mar 18, 2026, 15:54 ET Michelle Gong, M.D., M.S., Appointed Chair of Montefiore Einstein Department of Medicine
New England Journal of Medicine and JAMA. She has been recognized for her leadership with the Director's Award from the National Heart, Lung, and Blood Institute.Dr. Gong also strengthened her divisions' clinical services, including expanding the neuroscience ICU to support Montefiore
More news about: Albert Einstein College of Medicine
Mar 18, 2026, 15:02 ET Rosen Law Firm Encourages Immutep Ltd. Investors to Inquire About Securities Class Action Investigation - IMMP
Independent Data Monitoring Committee (IDMC) for the TACTI-004 Phase III study evaluating eftilagimod alfa ('efti') in patients in 1(st) line non-small cell lung cancer has recommended the discontinuation of the trial following a planned interim futility analysis in accordance with the study protocol." In addition,
More news about: THE ROSEN LAW FIRM, P. A.
Mar 18, 2026, 11:22 ET 總生存期顯著延長：蘆康沙妥珠單抗(sac-TMT) OptiTROP-Lung03研究OS最終分析結果亮相
2026年歐洲肺癌大會(ELCC)將於當地時間3月25日至28日在丹麥哥本哈根舉行。本次會議上，四川科倫博泰生物醫藥股份有限公司(「科倫博泰」或「公司」，6990.HK)自主研發的TROP2 ADC蘆康沙妥珠單抗( sac-TMT，亦稱SKB264/MK-2870)(佳泰萊®)關鍵臨床研究(OptiTROP-Lung03)的OS最終分析結果成功入選突破性摘要(LBA)(報告編號：LBA4)，屆時將由中山大學腫瘤防治中心楊雲鵬教授在小型口頭報告專場（Mini Oral Session）向全球學者彙報分享，摘要已發佈於ESMO Open期刊。
More news about: 科倫博泰